Events & Presentations

Date	Title
2024-08-08	Corporate Presentation

Date	Title
2024-11-11	PRESENTATION – SITC 2024 - A Phase I Study of AN4005, an Orally Available PD-L1 Inhibitor, in Patients with Advanced Tumors: Safety and Preliminary Efficacy
2024-09-14	PRESENTATION - ESMO 2024 - A Phase Ib Study of AN0025 in Combination With Definitive Chemoradiotherapy (dCRT) in Unresectable Locally Advanced or Locally Recurrent Esophageal Cancer (EC)
2023-10-22	PRESENTATION - ESMO 2023 - Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN
2023-05-31	PRESENTATION - ASCO 2023 - Combination of Immune and Genetic Biomarkers of Improved Efficacy to Buparlisib and Paclitaxel in Patients with SCCHN: BERIL-1 Sub-analysis
2019-09-29	PRESENTATION - ESMO 2019 - A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy Chemoradiotherapy (RTCRT) in Preoperative Treatment of Rectal Cancer

Upcoming Events